Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents.

× No keyword cloud information.

8 in total

1. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension.

Authors: M Sean McMurtry; Stephen L Archer; Dario C Altieri; Sebastien Bonnet; Alois Haromy; Gwyneth Harry; Sandra Bonnet; Lakshmi Puttagunta; Evangelos D Michelakis
Journal: J Clin Invest Date: 2005-06 Impact factor: 14.808

Review 2. Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies.

Authors: Helen Christou; Raouf A Khalil
Journal: Am J Physiol Heart Circ Physiol Date: 2022-02-25 Impact factor: 4.733

3. Dry Powder Formulation of Simvastatin Nanoparticles for Potential Application in Pulmonary Arterial Hypertension.

Authors: Shalaleh Zendehdel Baher; Shadi Yaqoubi; Kofi Asare-Addo; Hamed Hamishehkar; Ali Nokhodchi
Journal: Pharmaceutics Date: 2022-04-20 Impact factor: 6.525

Review 4. Can we improve outcome of congenital diaphragmatic hernia?

Authors: L van den Hout; I Sluiter; S Gischler; A De Klein; R Rottier; H Ijsselstijn; I Reiss; D Tibboel
Journal: Pediatr Surg Int Date: 2009-09 Impact factor: 1.827

Review 5. Considerations for numerical modeling of the pulmonary circulation--a review with a focus on pulmonary hypertension.

Authors: V O Kheyfets; W O'Dell; T Smith; J J Reilly; E A Finol
Journal: J Biomech Eng Date: 2013-06 Impact factor: 2.097

Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents.

1. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension.

Review 2. Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies.

3. Dry Powder Formulation of Simvastatin Nanoparticles for Potential Application in Pulmonary Arterial Hypertension.

Review 4. Can we improve outcome of congenital diaphragmatic hernia?

Review 5. Considerations for numerical modeling of the pulmonary circulation--a review with a focus on pulmonary hypertension.

6. Pulmonary Hypertension: Scientometric Analysis and Density-Equalizing Mapping.

Review 7. The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension.

8. Simvastatin restores down-regulated GATA-6 expression in pulmonary hypertensive rats.